$EVOK
Evoke Pharma Inc

2015 Q1 Form 10-Q Financial Statement

#000156459015004303 Filed on May 14, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.030M $740.0K $1.070M
YoY Change -3.74% -21.28% 386.36%
% of Gross Profit
Research & Development $2.420M $2.176M $1.852M
YoY Change 30.66% 241.97% 1568.86%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.445M $2.176M $2.923M
YoY Change 17.88% 241.97% 780.22%
Operating Profit -$3.445M -$2.923M
YoY Change 17.88% 780.22%
Interest Expense $77.05K -$10.00K $36.94K
YoY Change 108.55% -75.0% -192.36%
% of Operating Profit
Other Income/Expense, Net -$75.53K $0.00 -$32.89K
YoY Change 129.64% -79.69%
Pretax Income -$3.520M -$2.920M -$2.960M
YoY Change 18.92% 80.25% 504.08%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.521M -$2.920M -$2.955M
YoY Change 19.13% 80.6% 498.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$577.0K -$482.6K -$493.3K
COMMON SHARES
Basic Shares Outstanding 6.137M 6.112M 6.100M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.69M $14.16M $21.84M
YoY Change -46.47% -41.49% 1207.78%
Cash & Equivalents $11.69M $14.16M $21.84M
Short-Term Investments
Other Short-Term Assets $23.62K $161.4K $180.0K
YoY Change -86.88% -29.81%
Inventory
Prepaid Expenses $931.5K $176.2K
Receivables
Other Receivables
Total Short-Term Assets $12.57M $15.25M $22.01M
YoY Change -42.88% -37.58% 1218.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $47.12K $53.02K $555.5K
YoY Change -91.52% -90.45% 5455.05%
Total Long-Term Assets $47.12K $53.02K $555.5K
YoY Change -91.52% -90.45% 5455.05%
TOTAL ASSETS
Total Short-Term Assets $12.57M $15.25M $22.01M
Total Long-Term Assets $47.12K $53.02K $555.5K
Total Assets $12.62M $15.30M $22.57M
YoY Change -44.07% -38.76% 1243.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.350M $1.010M $1.120M
YoY Change 20.54% 260.71% 314.81%
Accrued Expenses $420.0K $700.0K $390.0K
YoY Change 7.69% 25.0% 129.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $712.9K $126.8K $1.443M
YoY Change -50.58% -91.21%
Total Short-Term Liabilities $2.500M $1.848M $2.944M
YoY Change -15.09% -19.12% 339.39%
LONG-TERM LIABILITIES
Long-Term Debt $3.688M $4.196M $1.157M
YoY Change 218.86% 177.64% -60.66%
Other Long-Term Liabilities $20.00K
YoY Change
Total Long-Term Liabilities $3.688M $4.196M $1.157M
YoY Change 218.86% 176.39% -60.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.500M $1.848M $2.944M
Total Long-Term Liabilities $3.688M $4.196M $1.157M
Total Liabilities $6.188M $6.044M $4.116M
YoY Change 50.33% 58.93% 14.02%
SHAREHOLDERS EQUITY
Retained Earnings -$39.46M -$35.94M
YoY Change 58.38%
Common Stock $45.89M $45.13M $610.00
YoY Change 7523378.85% 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.433M $9.189M $18.45M
YoY Change
Total Liabilities & Shareholders Equity $12.62M $15.23M $22.57M
YoY Change -44.07% -39.03% 1243.29%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q1
OPERATING ACTIVITIES
Net Income -$3.521M -$2.920M -$2.955M
YoY Change 19.13% 80.6% 498.29%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.000M -$2.520M -$2.001M
YoY Change 49.95% 33.33% 348.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $531.6K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 530.0K 4.500M -360.6K
YoY Change -246.99% 91.49% -118.03%
NET CHANGE
Cash From Operating Activities -3.000M -2.520M -2.001M
Cash From Investing Activities
Cash From Financing Activities 530.0K 4.500M -360.6K
Net Change In Cash -2.470M 1.980M -2.361M
YoY Change 4.61% 330.43% -251.99%
FREE CASH FLOW
Cash From Operating Activities -$3.000M -$2.520M -$2.001M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1871617
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-75526
CY2015Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1353147
CY2015Q1 us-gaap Assets Current
AssetsCurrent
12574112
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
424597
CY2015Q1 us-gaap Assets
Assets
12621229
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
23624
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3445222
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2922595
CY2014Q4 us-gaap Assets Current
AssetsCurrent
15248706
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1011629
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
697245
CY2014Q4 us-gaap Assets
Assets
15301729
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
47117
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
161436
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39459897
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
6433324
CY2015Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
712930
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9015
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2499689
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12621229
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6198967
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6198967
CY2015Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2419961
CY2014Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1852116
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3200000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53023
CY2014Q4 us-gaap Liabilities
Liabilities
6113065
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12313
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
150430
CY2015Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3688216
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4241448
CY2015Q1 us-gaap Liabilities
Liabilities
6187905
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1105703
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6112091
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
223310
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6112091
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
620
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
611
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45892601
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45127202
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35939149
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
9188664
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15301729
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2015Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1522
CY2014Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4055
CY2015Q1 us-gaap Interest Expense
InterestExpense
77048
CY2014Q1 us-gaap Interest Expense
InterestExpense
36944
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32889
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3520748
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2955484
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6103783
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6002936
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
371600
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
15174
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
5816
CY2015Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
3298
CY2014Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8688
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-73333
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58015
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
68870
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
659038
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2995069
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2000617
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
360576
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
531620
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
531620
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-360576
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2463449
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2361193
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21835498
CY2015Q1 us-gaap Interest Paid
InterestPaid
41250
CY2014Q1 us-gaap Interest Paid
InterestPaid
32495
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2015Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2014Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
94375
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
732090
CY2015Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0217
CY2015Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P10Y
CY2015Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7719
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
108122
CY2014Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
108122
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2015Q1 evok Legal Accounting And Filing Fees
LegalAccountingAndFilingFees
138000
CY2015Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
111000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371600
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
223310

Files In Submission

Name View Source Status
0001564590-15-004303-index-headers.html Edgar Link pending
0001564590-15-004303-index.html Edgar Link pending
0001564590-15-004303.txt Edgar Link pending
0001564590-15-004303-xbrl.zip Edgar Link pending
evok-10q_20150331.htm Edgar Link pending
evok-20150331.xml Edgar Link completed
evok-20150331.xsd Edgar Link pending
evok-20150331_cal.xml Edgar Link unprocessable
evok-20150331_def.xml Edgar Link unprocessable
evok-20150331_lab.xml Edgar Link unprocessable
evok-20150331_pre.xml Edgar Link unprocessable
evok-ex101_20150331260.htm Edgar Link pending
evok-ex311_201503318.htm Edgar Link pending
evok-ex312_201503319.htm Edgar Link pending
evok-ex321_201503317.htm Edgar Link pending
evok-ex322_201503316.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending